The University of Queensland will play a key role in a national effort to revolutionize treatment for men with prostate cancer.

The company’s strong financials and innovative collaborations, such as its partnership with AdvanCell to develop targeted cancer therapies, further enhance its appeal.

Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It develops, manufactures, discovers, and sells pharmaceutical products. These goods cover ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology ...

Cancer treatment start-up AdvanCell’s raised $171 million and Aravax raised $66 million to help grow its allergy symptom reduction products. The average deal size rose to an all-time high over ...

While biotech and medtech startups dominated total capital raised — buoyed by a $179 million raise by Harrison.ai and a $178.6 million round for cancer treatment startup AdvanCell — AI edged ...

SYDNEY--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced $18M in Australian Federal Government Funding from the ...

The company also represents Advancell expandable microspheres and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion dollar, ...

The company also represents Advancell expandable microspheres and S-LEC BK polyvinyl acetal resins. Sekisui Specialty Chemicals is a subsidiary of the Sekisui Chemical Group, a multibillion dollar ...